The purpose of this research study is to test the safety and to explore the effectiveness of
infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with
Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid
Leukemia (AML).
Names of the study therapies involved in this study are:
- Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell
infusion
- CIML NK (a cellular therapy)
- IL-2 (a recombinant, human glycoprotein)
- Venetoclax (a selective inhibitor of BCL-2 protein)